产品
编 号：F290023
分子式：C26H31N3O5S
分子量：497.61
分子式：C26H31N3O5S
分子量：497.61
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
25mg
询价
询价
50mg
询价
询价
结构图
CAS No: 244192-94-7
产品详情
生物活性：
L748337 is a potent β3-adrenergic receptor antagonist and displays selectivity over?β1?and?β2?receptors. The Ki values of L748337 for β3-,?β2- and?β1-adrenoceptors are 4.0 nM, 204 nM and 390 nM, respectively. L748337 couples predominantly to Gi to activate MAPK signaling and increases phosphorylation of Erk1/2 with pEC50 value of 11.6. L748337 can be used for the research of cancer, nonalcoholic fatty liver disease (NAFLD), and cardiovascular related diseases.
体内研究：
L-748337 (intraperitoneal?injection; 5 mg/kg; beginning 10 days until D18) decreases the growth of melanoma induced by B16F10 cell inoculation and decreases tumor vasculature in mice.Animal Model:Fifty male C57BL/6 J mice (8 weeks of age) bearing syngeneic B16F10 cell
Dosage:5 mg/kg
Administration:Beginning 10 days until D18
Result:Exhibited anti-cancer effects.
体外研究：
L748337 (1 μM) inhibits iNOS expression in B16F10 cells.
L748337 is a potent β3-adrenergic receptor antagonist and displays selectivity over?β1?and?β2?receptors. The Ki values of L748337 for β3-,?β2- and?β1-adrenoceptors are 4.0 nM, 204 nM and 390 nM, respectively. L748337 couples predominantly to Gi to activate MAPK signaling and increases phosphorylation of Erk1/2 with pEC50 value of 11.6. L748337 can be used for the research of cancer, nonalcoholic fatty liver disease (NAFLD), and cardiovascular related diseases.
体内研究：
L-748337 (intraperitoneal?injection; 5 mg/kg; beginning 10 days until D18) decreases the growth of melanoma induced by B16F10 cell inoculation and decreases tumor vasculature in mice.Animal Model:Fifty male C57BL/6 J mice (8 weeks of age) bearing syngeneic B16F10 cell
Dosage:5 mg/kg
Administration:Beginning 10 days until D18
Result:Exhibited anti-cancer effects.
体外研究：
L748337 (1 μM) inhibits iNOS expression in B16F10 cells.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备